Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SCCL
MCID: SML038
MIFTS: 65

Small Cell Cancer of the Lung (SCCL)

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Small Cell Cancer of the Lung

About this section

MalaCards integrated aliases for Small Cell Cancer of the Lung:

Name: Small Cell Cancer of the Lung 56
Small Cell Lung Cancer 74 52 58 36 29 54 6
Lung Small Cell Carcinoma 12 52 15
Small-Cell Cancer of Lung 56 13
Small Cell Lung Carcinoma 43 17
Sclc 56 58
Small Cell Neuroendocrine Carcinoma of the Lung 52
Small Cell Carcinoma of Lung 71
Cancer, Lung, Small Cell 39
Carcinoma, Small Cell 71
Oat Cell Lung Cancer 52
Sclc; Sccl 56
Sclc1 56
Sccl 56

Characteristics:

Orphanet epidemiological data:

58
small cell lung cancer
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
small cell cancer of the lung:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:5409
OMIM 56 182280
KEGG 36 H00013
MeSH 43 D055752
NCIt 49 C4917
SNOMED-CT 67 254632001
ICD10 via Orphanet 33 C34.9
UMLS via Orphanet 72 C0149925
Orphanet 58 ORPHA70573
MedGen 41 C0149925
SNOMED-CT via HPO 68 126713003 263681008
UMLS 71 C0149925 C0262584
Sources

Summaries for Small Cell Cancer of the Lung

About this section
KEGG : 36 Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Small cell lung carcinoma (SCLC) is a highly aggressive neoplasm, which accounts for approximately 25% of all lung cancer cases. Molecular mechanisms altered in SCLC include induced expression of oncogene, MYC, and loss of tumorsuppressor genes, such as p53, PTEN, RB, and FHIT. The overexpression of MYC proteins in SCLC is largely a result of gene amplification. Such overexpression leads to more rapid proliferation and loss of terminal differentiation. Mutation or deletion of p53 or PTEN can lead to more rapid proliferation and reduced apoptosis. The retinoblastoma gene RB1 encodes a nuclear phosphoprotein that helps to regulate cell-cycle progression. The fragile histidine triad gene FHIT encodes the enzyme diadenosine triphosphate hydrolase, which is thought to have an indirect role in proapoptosis and cell-cycle control.

MalaCards based summary : Small Cell Cancer of the Lung, also known as small cell lung cancer, is related to small cell carcinoma of the bladder and lung combined type small cell carcinoma. An important gene associated with Small Cell Cancer of the Lung is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Small cell lung cancer and MicroRNAs in cancer. The drugs Sunitinib and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are neoplasm of the lung and neoplasm

Disease Ontology : 12 A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells and is located in the lung.

Wikipedia : 74 Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung,... more...

More information from OMIM: 182280
Sources

Related Diseases for Small Cell Cancer of the Lung

About this section

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Small Cell Cancer of the Lung via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1266)
# Related Disease Score Top Affiliating Genes
1 small cell carcinoma of the bladder 33.1 SYP NKX2-1 KRT20 ENO2 CHGA
2 lung combined type small cell carcinoma 32.9 SYP NCAM1
3 lung squamous cell carcinoma 32.3 TUG1 TP53 PTEN PIK3CA CCAT2
4 lung cancer 32.3 TUG1 TP73 TP53 SYP RB1 PTEN
5 adenosquamous carcinoma 32.0 TP53 SYP PTEN PIK3CA NKX2-1 CHGA
6 thyroid carcinoma 31.8 PTEN PIK3CA NKX2-1
7 in situ carcinoma 31.6 TP53 PTEN PIK3CA
8 mucinous adenocarcinoma 31.6 TP53 NKX2-1 KRT20
9 spindle cell carcinoma 31.6 SYP ENO2 CHGA
10 lung large cell carcinoma 31.6 SYP NKX2-1 NCAM1 CHGA
11 lung benign neoplasm 31.6 TP53 SYP RB1 NKX2-1 NCAM1 KRT20
12 osteogenic sarcoma 31.5 TUG1 TP53 RB1 MALAT1 HOTTIP HOTAIR
13 appendix adenocarcinoma 31.5 SYP KRT20 CHGA
14 glioblastoma multiforme 31.5 TP53 SYP RB1 PTEN PIK3CA MIR21
15 thymoma 31.5 TP53 SYP PIK3CA NKX2-1 ENO2
16 polyploidy 31.5 TP73 TP53
17 papillary adenocarcinoma 31.3 TP53 NKX2-1 MIR21
18 esophageal cancer 31.3 TP73 TP53 RB1 PTEN PIK3CA MIR21
19 lung oat cell carcinoma 31.3 SYP POMC GRP ENO2 CHGA
20 renal cell carcinoma, nonpapillary 31.3 TUG1 TP53 PTEN PIK3CA NKX2-1 MIR21
21 kidney cancer 31.3 TP53 PTEN PIK3CA MIR21 MALAT1 HOTAIR
22 bladder cancer 31.3 TUG1 TP53 RB1 PTEN PIK3CA MIR21
23 adenoma 31.3 TP53 SYP POMC PIK3CA KRT20 CHGA
24 carcinosarcoma 31.3 TP53 PTEN PIK3CA
25 squamous cell carcinoma, head and neck 31.2 TP73 TP53 RB1 PTEN PIK3CA MIR21
26 carcinoid tumors, intestinal 31.2 SYP NKX2-1 ENO2 CHGA
27 glioma 31.2 TP53 PTEN PIK3CA MIR21 MALAT1 HOTTIP
28 leukemia, acute myeloid 31.2 TUG1 TP53 PTEN PIK3CA NCAM1 MIR21
29 nasopharyngeal carcinoma 31.2 TP53 PTEN PIK3CA MIR21 MALAT1 HOTAIR
30 retinitis pigmentosa 11 31.2 TP53 PTEN HOTAIR
31 acute promyelocytic leukemia 31.2 TP73 TP53 RB1 PTEN PIK3CA NCAM1
32 pancreatic ductal adenocarcinoma 31.2 TP53 PTEN MIR21 MALAT1 HOTTIP HOTAIR
33 myeloma, multiple 31.1 TUG1 TP53 PTEN NCAM1 MIR21 MALAT1
34 intrahepatic cholangiocarcinoma 31.1 TUG1 TP53 PTEN KRT20 CCAT2
35 pulmonary large cell neuroendocrine carcinoma 31.1 SYP NCAM1 CHGA
36 ovarian cancer 31.1 TUG1 TP73 TP53 RB1 PTEN PIK3CA
37 brain cancer 31.1 TP73 TP53 SYP RB1 PTEN PIK3CA
38 hepatocellular carcinoma 31.1 TUG1 TP73 TP53 RB1 PTEN PIK3CA
39 papilloma 31.1 TP53 RB1 PTEN KRT20
40 retinoblastoma 31.1 TP53 SYP RB1 MALAT1 HOTAIR ENO2
41 pituitary adenoma 31.1 POMC MALAT1 HOTAIR CHGA CCAT2
42 skin carcinoma 31.0 TP53 POMC MIR21 KRT20 CHGA
43 pancreatic cancer 31.0 TUG1 TP53 RB1 PTEN PIK3CA MIR21
44 hemangioma 31.0 TP53 SYP PTEN NKX2-1 ENO2 CHGA
45 adenoid cystic carcinoma 31.0 TP53 PTEN PIK3CA NCAM1 KRT20
46 liposarcoma 31.0 TP53 RB1 PTEN PIK3CA
47 small cell carcinoma 31.0 TP53 SYP PTEN NKX2-1 NCAM1 KRT20
48 grade iii astrocytoma 31.0 TP73 TP53 RB1 PTEN
49 oral squamous cell carcinoma 31.0 TUG1 TP53 PTEN MIR21 MALAT1 HOTAIR
50 colorectal adenocarcinoma 31.0 TP53 PTEN NKX2-1 KRT20 CHGA

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung:



Diseases related to Small Cell Cancer of the Lung
Sources

Symptoms & Phenotypes for Small Cell Cancer of the Lung

About this section

Human phenotypes related to Small Cell Cancer of the Lung:

31
# Description HPO Frequency HPO Source Accession
1 neoplasm of the lung 31 HP:0100526

Symptoms via clinical synopsis from OMIM:

56
Oncology:
small-cell lung cancer

Lab:
3p23-p14 chromosome deletion in tumor

Misc:
sensitive to chemotherapy and radiotherapy

Clinical features from OMIM:

182280

MGI Mouse Phenotypes related to Small Cell Cancer of the Lung:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.5 NKX2-1 PIK3CA POMC PTEN RB1 TP53
2 nervous system MP:0003631 9.4 CHGA ENO2 GRP NCAM1 NKX2-1 PIK3CA
Sources

Drugs & Therapeutics for Small Cell Cancer of the Lung

About this section

Drugs for Small Cell Cancer of the Lung (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 725)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 4 557795-19-4, 341031-54-7 5329102
2
Vinblastine Approved Phase 4 865-21-4 241903 13342
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Caffeine Approved Phase 4 58-08-2 2519
5
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
6
tannic acid Approved Phase 4 1401-55-4
7
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
13
Remifentanil Approved Phase 4 132875-61-7 60815
14
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
15
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
16
Vemurafenib Approved Phase 4 918504-65-1 23252090 42611257
17
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
21
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
22
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
23
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
24
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
25 Flurbiprofen axetil Investigational Phase 4 91503-79-6
26 acivicin Phase 4
27 Cholinergic Agents Phase 4
28 Nicotinic Agonists Phase 4
29 N-Methylaspartate Phase 4
30
Bilirubin Phase 4 69853-43-6, 635-65-4 21252250 5280352
31 Hypnotics and Sedatives Phase 4
32 Anesthetics, General Phase 4
33 Anesthetics, Intravenous Phase 4
34 Platelet Aggregation Inhibitors Phase 4
35 Anesthetics, Inhalation Phase 4
36
Apatinib Phase 4 811803-05-1
37 Endostatins Phase 4 71581480
38 Hormones Phase 4
39 Hormone Antagonists Phase 4
40 Gastrointestinal Agents Phase 4
41 Antiemetics Phase 4
42 Antineoplastic Agents, Hormonal Phase 4
43
protease inhibitors Phase 4
44 HIV Protease Inhibitors Phase 4
45 glucocorticoids Phase 4
46 BB 1101 Phase 4
47 Cyclooxygenase Inhibitors Phase 4
48 Dexamethasone 21-phosphate Phase 4
49 Anti-Anxiety Agents Phase 4
50
L-Alanine Nutraceutical Phase 4 56-41-7 5950

Interventional clinical trials:

(show top 50) (show all 5880)
# Name Status NCT ID Phase Drugs
1 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
2 Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX) Unknown status NCT03134456 Phase 4 Pembrolizumab Injection
3 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
4 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
5 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
6 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (â…¢ A / â…¢ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
7 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
8 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
9 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
10 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
11 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
12 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
13 A Phase â…£,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer) Unknown status NCT02778893 Phase 4 Conmana;Thalidomide
14 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
15 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
16 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
17 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
18 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
19 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
20 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
21 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
22 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
23 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
24 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
25 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
26 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
27 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
28 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
29 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
30 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
31 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
32 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
33 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
34 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
35 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage â…¢A Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
36 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
37 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
38 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
39 A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations Completed NCT02514174 Phase 4 Afatinib
40 Ensure Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva®) and Erlotinib After the Time of Disease Progression in Chinese Population Enrolled in the Ensure Trial Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy
41 An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSAâ„¢) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT01203917 Phase 4 Gefitinib
42 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
43 An Open , Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy Completed NCT01465243 Phase 4 Icotinib
44 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
45 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
46 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
47 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
48 Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Completed NCT03092986 Phase 4 Paclitaxel;Carboplatin;Cisplatin;Vinblastine Sulfate
49 Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study. Completed NCT01848613 Phase 4 Vinorelbine
50 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab

Search NIH Clinical Center for Small Cell Cancer of the Lung

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
Teniposide
Topotecan
Topotecan Hydrochloride

Cochrane evidence based reviews: small cell lung carcinoma

Sources

Genetic Tests for Small Cell Cancer of the Lung

About this section

Genetic tests related to Small Cell Cancer of the Lung:

# Genetic test Affiliating Genes
1 Small Cell Lung Cancer 29 RB1
Sources

Anatomical Context for Small Cell Cancer of the Lung

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Small Cell Cancer of the Lung:

19
Lung

MalaCards organs/tissues related to Small Cell Cancer of the Lung:

40
Lung, Brain, Lymph Node, Breast, Testes, T Cells, Bone
Sources

Publications for Small Cell Cancer of the Lung

About this section

Articles related to Small Cell Cancer of the Lung:

(show top 50) (show all 30868)
# Title Authors PMID Year
1
Comprehensive genomic profiles of small cell lung cancer. 61 56
26168399 2015
2
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. 56 61
22941189 2012
3
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. 61 56
22941188 2012
4
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. 61 56
12629553 2003
5
Microsatellite alterations in plasma DNA of small cell lung cancer patients. 61 56
8782463 1996
6
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. 56 61
1672284 1991
7
Localization of human ERBA2 to the 3p22----3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer. 56 61
2848257 1988
8
Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors. 61 56
2900253 1988
9
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. 56 61
2821400 1987
10
Loss of heterozygosity for a chromosome 3 sequence presumably at 3p21 in small cell lung cancer. 61 56
2885082 1987
11
Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. 61 56
3030544 1987
12
A unique cell-surface protein phenotype distinguishes human small-cell from non-small-cell lung cancer. 56 61
6289311 1982
13
A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). 61 56
6286098 1982
14
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). 56 61
6274023 1982
15
Definition of a tumor suppressor locus within human chromosome 3p21-p22. 56
1438292 1992
16
Three distinct regions involved in 3p deletion in human lung cancer. 56
1347916 1992
17
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. 6
2594029 1989
18
Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. 56
2536219 1989
19
Molecular genetics of lung cancer. 56
3289123 1988
20
Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. 56
2892196 1987
21
Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. 56
2825033 1987
22
Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. 56
2821398 1987
23
Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. 56
2998591 1985
24
A 3p deletion in small cell lung carcinoma. 56
2982478 1985
25
Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. 56
6089338 1984
26
Human lung small-cell carcinoma contains bombesin. 56
6285381 1982
27
Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. 56
6265067 1981
28
Neuron-specific enolase is produced by neuroendocrine tumours. 56
6111674 1981
29
Cytogenetic effects of cigarette smoke condensates in vitro and in vivo. 56
7333590 1981
30
MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. 46
20508945 2011
31
Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells. 54 61
20206622 2010
32
Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth. 61 54
20015838 2010
33
Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. 61 54
20004564 2010
34
Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. 54 61
20078550 2009
35
Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer. 54 61
19889201 2009
36
Flow cytometric detection of small cell lung cancer cells with aberrant CD45 expression in micrometastatic bone marrow. 54 61
19674995 2009
37
Caveolin-1 is an important factor for the metastasis and proliferation of human small cell lung cancer NCI-H446 cell. 61 54
19718715 2009
38
Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. 54 61
19679880 2009
39
Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. 54 61
19372561 2009
40
Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology. 54 61
19390995 2009
41
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. 54 61
19149760 2009
42
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. 61 54
19047109 2008
43
[Relationship between vascular endothelial growth factor C expression level and lymph node metastasis in non small cell lung cancer]. 54 61
19080076 2008
44
Epidermal growth factor receptor mutations in small cell lung cancer. 61 54
18829487 2008
45
ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. 61 54
19031951 2008
46
[Effect of FGF-2 on survivin and subcellular location of Smac in human small cell lung cancer cell NCI-H446]. 61 54
18772510 2008
47
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. 61 54
18519752 2008
48
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. 54 61
18381439 2008
49
EGFR-immunohistochemistry in colorectal cancer and non-small cell lung cancer: comparison of 3 commercially available EGFR-antibodies. 54 61
18720932 2008
50
Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells. 54 61
17906699 2008
Sources

Variations for Small Cell Cancer of the Lung

About this section

ClinVar genetic disease variations for Small Cell Cancer of the Lung:

6 (show top 50) (show all 106) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 subset of 54 genes: SPAST chr2:29446394..42552694 inversioninversion Pathogenic 487484 2:29446394-42552694
2 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
3 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
4 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
5 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
6 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
7 RB1 NM_000321.2(RB1):c.1981C>T (p.Arg661Trp)SNV Pathogenic 13087 rs137853294 13:49033844-49033844 13:48459708-48459708
8 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
9 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
10 RB1 NM_000321.2(RB1):c.1215+1G>ASNV Pathogenic 126832 rs587776783 13:48947629-48947629 13:48373493-48373493
11 TP53 NM_001126112.2(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
12 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
13 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro)SNV Pathogenic 142018 rs121909229 10:89692905-89692905 10:87933148-87933148
14 TP53 NM_001126112.2(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
15 TP53 NM_001126112.2(TP53):c.374C>A (p.Thr125Lys)SNV Pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
16 TP53 NM_001126112.2(TP53):c.517G>A (p.Val173Met)SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
17 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
18 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
19 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
20 TP53 NM_001126112.2(TP53):c.730G>A (p.Gly244Ser)SNV Pathogenic 376600 rs1057519989 17:7577551-7577551 17:7674233-7674233
21 TP53 NM_001126112.2(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
22 TP53 NM_001126112.2(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
23 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
24 TP53 NM_001126112.2(TP53):c.644G>T (p.Ser215Ile)SNV Pathogenic 376660 rs587782177 17:7578205-7578205 17:7674887-7674887
25 TP53 NM_001126112.2(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
26 TP53 NM_001126112.2(TP53):c.817C>A (p.Arg273Ser)SNV Pathogenic/Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
27 TP53 NM_001126112.2(TP53):c.374C>G (p.Thr125Arg)SNV Pathogenic/Likely pathogenic 376667 rs786201057 17:7579313-7579313 17:7675995-7675995
28 TP53 NM_001126112.2(TP53):c.700T>C (p.Tyr234His)SNV Pathogenic/Likely pathogenic 376691 rs864622237 17:7577581-7577581 17:7674263-7674263
29 PTEN NM_000314.7(PTEN):c.389G>T (p.Arg130Leu)SNV Pathogenic/Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
30 TP53 NM_001126112.2(TP53):c.731G>A (p.Gly244Asp)SNV Pathogenic/Likely pathogenic 372785 rs985033810 17:7577550-7577550 17:7674232-7674232
31 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
32 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)SNV Pathogenic/Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
33 TP53 NM_001126112.2(TP53):c.818G>C (p.Arg273Pro)SNV Pathogenic/Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
34 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)SNV Pathogenic/Likely pathogenic 217293 rs121913275 3:178936093-178936093 3:179218305-179218305
35 TP53 NM_001126112.2(TP53):c.701A>G (p.Tyr234Cys)SNV Pathogenic/Likely pathogenic 127820 rs587780073 17:7577580-7577580 17:7674262-7674262
36 TP53 NM_001126112.2(TP53):c.535C>T (p.His179Tyr)SNV Pathogenic/Likely pathogenic 127815 rs587780070 17:7578395-7578395 17:7675077-7675077
37 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys)SNV Pathogenic/Likely pathogenic 31944 rs121913273 3:178936082-178936082 3:179218294-179218294
38 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)SNV Pathogenic/Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
39 RB1 NM_000321.2(RB1):c.2242G>T (p.Glu748Ter)SNV Pathogenic/Likely pathogenic 13078 rs121913297 13:49039164-49039164 13:48465028-48465028
40 TP53 NM_001126112.2(TP53):c.578A>G (p.His193Arg)SNV Likely pathogenic 184979 rs786201838 17:7578271-7578271 17:7674953-7674953
41 TP53 NM_001126112.2(TP53):c.487T>G (p.Tyr163Asp)SNV Likely pathogenic 187052 rs786203436 17:7578443-7578443 17:7675125-7675125
42 TP53 NM_001126112.2(TP53):c.587G>C (p.Arg196Pro)SNV Likely pathogenic 231165 rs483352697 17:7578262-7578262 17:7674944-7674944
43 RB1 NM_000321.2(RB1):c.2117G>T (p.Cys706Phe)SNV Likely pathogenic 376330 rs121913295 13:49037877-49037877 13:48463741-48463741
44 B2M NM_004048.3(B2M):c.3G>A (p.Met1Ile)SNV Likely pathogenic 376368 rs1057519877 15:45003747-45003747 15:44711549-44711549
45 B2M NM_004048.3(B2M):c.1A>G (p.Met1Val)SNV Likely pathogenic 376369 rs1023835002 15:45003745-45003745 15:44711547-44711547
46 B2M NM_004048.3(B2M):c.1A>T (p.Met1Leu)SNV Likely pathogenic 376370 rs1023835002 15:45003745-45003745 15:44711547-44711547
47 B2M NM_004048.3(B2M):c.2T>C (p.Met1Thr)SNV Likely pathogenic 376371 rs1057519879 15:45003746-45003746 15:44711548-44711548
48 B2M NM_004048.3(B2M):c.2T>G (p.Met1Arg)SNV Likely pathogenic 376372 rs1057519879 15:45003746-45003746 15:44711548-44711548
49 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala)SNV Likely pathogenic 376473 rs1057519927 3:178936083-178936083 3:179218295-179218295
50 PIK3CA NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val)SNV Likely pathogenic 376474 rs1057519927 3:178936083-178936083 3:179218295-179218295

Copy number variations for Small Cell Cancer of the Lung from CNVD:

7 (show top 50) (show all 515)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 15909 1 120235683 147296355 Substitutions and indels small cell lung cancer
2 18774 1 147306435 159745095 Substitutions and indels small cell lung cancer
3 21590 1 159753915 159864147 Substitutions and indels small cell lung cancer
4 21631 1 159879159 167481135 Substitutions and indels small cell lung cancer
5 22562 1 167488767 167515635 Substitutions and indels small cell lung cancer
6 22575 1 167524383 182844003 Substitutions and indels small cell lung cancer
7 22643 1 16801095 16840107 Substitutions and indels small cell lung cancer
8 22724 1 16861959 29150031 Substitutions and indels small cell lung cancer
9 24621 1 182849019 182888703 Substitutions and indels small cell lung cancer
10 24623 1 182893695 194979795 Substitutions and indels small cell lung cancer
11 25853 1 194993223 195074031 Substitutions and indels small cell lung cancer
12 25942 1 195088143 205083387 Substitutions and indels small cell lung cancer
13 27160 1 205088907 205109547 Substitutions and indels small cell lung cancer
14 27163 1 205114395 208124379 Substitutions and indels small cell lung cancer
15 27411 1 208129227 208155879 Substitutions and indels small cell lung cancer
16 27424 1 208162923 222138663 Substitutions and indels small cell lung cancer
17 28412 1 222150063 222281979 Substitutions and indels small cell lung cancer
18 28435 1 222297471 247249719 Substitutions and indels small cell lung cancer
19 31650 1 29155527 30043083 Substitutions and indels small cell lung cancer
20 31718 1 30048807 41173191 Substitutions and indels small cell lung cancer
21 32828 1 39746 16783059 Substitutions and indels small cell lung cancer
22 33011 1 41174800 41175800 Intrachromosomal rearrangement small cell lung cancer
23 33013 1 41178543 42371163 Substitutions and indels small cell lung cancer
24 33099 1 42374208 42375208 Intrachromosomal rearrangement small cell lung cancer
25 33100 1 42376011 42579327 Substitutions and indels small cell lung cancer
26 33116 1 42583395 42584395 Intrachromosomal rearrangement small cell lung cancer
27 33117 1 42584427 44255643 Substitutions and indels small cell lung cancer
28 33294 1 44259752 44260752 Intrachromosomal rearrangement small cell lung cancer
29 33295 1 44260511 44261511 Intrachromosomal rearrangement small cell lung cancer
30 33296 1 44260527 44275323 Substitutions and indels small cell lung cancer
31 33300 1 44279330 44280330 Intrachromosomal rearrangement small cell lung cancer
32 33301 1 44279742 44280742 Intrachromosomal rearrangement small cell lung cancer
33 33302 1 44280303 48578211 Substitutions and indels small cell lung cancer
34 33819 1 48580747 48581747 Intrachromosomal rearrangement small cell lung cancer
35 33821 1 48583227 51275739 Substitutions and indels small cell lung cancer
36 33980 1 51279608 51280608 Intrachromosomal rearrangement small cell lung cancer
37 33981 1 51281079 54467547 Substitutions and indels small cell lung cancer
38 34296 1 54469360 54470360 Intrachromosomal rearrangement small cell lung cancer
39 34297 1 54473247 54557103 Substitutions and indels small cell lung cancer
40 34301 1 54561497 54562497 Intrachromosomal rearrangement small cell lung cancer
41 34302 1 54562083 54649251 Substitutions and indels small cell lung cancer
42 34322 1 54652634 54653634 Intrachromosomal rearrangement small cell lung cancer
43 34323 1 54654159 57627915 Substitutions and indels small cell lung cancer
44 34908 1 57632775 57657135 Substitutions and indels small cell lung cancer
45 34910 1 57661947 72536187 Substitutions and indels small cell lung cancer
46 36221 1 72541191 72583059 Substitutions and indels small cell lung cancer
47 36257 1 72587919 85749039 Substitutions and indels small cell lung cancer
48 37122 1 85755495 85774959 Substitutions and indels small cell lung cancer
49 37129 1 85779879 120230763 Substitutions and indels small cell lung cancer
50 41421 10 17866791 18173655 Substitutions and indels small cell lung cancer
Sources

Expression for Small Cell Cancer of the Lung

About this section
Search GEO for disease gene expression data for Small Cell Cancer of the Lung.
Sources

Pathways for Small Cell Cancer of the Lung

About this section

Pathways related to Small Cell Cancer of the Lung according to KEGG:

36
# Name Kegg Source Accession
1 Small cell lung cancer hsa05222
2 MicroRNAs in cancer hsa05206

Pathways related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
12.19 SYP POMC NKX2-1 NCAM1 ENO2
2
DNA Damage Response 1
Show member pathways
 12.17 TP73 TP53 RB1 PTEN
3
Human T-cell leukemia virus 1 infection 36
12.12 TP53 RB1 PTEN PIK3CA
4
Cellular senescence (KEGG) 36
11.82 TP53 RB1 PTEN PIK3CA
5
Direct p53 effectors 1
11.58 TP73 TP53 RB1 PTEN
6
Central carbon metabolism in cancer 36
11.48 TP53 PTEN PIK3CA
7
Pathways Affected in Adenoid Cystic Carcinoma 1
11.43 TP53 PTEN PIK3CA
8
DNA Damage Response (only ATM dependent) 1
11.32 TP73 TP53 PTEN PIK3CA
9
Copper homeostasis 1
11.31 TP53 PTEN PIK3CA
10
Integrated Cancer Pathway 1
11.21 TP53 RB1 PTEN
11
Small cell lung cancer 36
10.89 TP53 RB1 PTEN PIK3CA
12
LncRNA-mediated mechanisms of therapeutic resistance 1
10.59 TP53 HOTAIR
Sources

GO Terms for Small Cell Cancer of the Lung

About this section

Biological processes related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.13 RB1 PTEN MIR21
2 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 8.62 GRP CHGA

Molecular functions related to Small Cell Cancer of the Lung according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region DNA binding GO:0001012 8.96 RB1 NKX2-1
2 MDM2/MDM4 family protein binding GO:0097371 8.62 TP73 TP53
Sources

Sources for Small Cell Cancer of the Lung

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....